Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. Over the next few ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Penserra Capital Management significantly reduced its stake in Vertex Pharmaceuticals, dropping 81% of its shares in the ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals is currently pushing against the $467.85 resistance level as its stock maintains an upward trend.

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.